Chondrosarcoma

Diseases /

Back to Diseases List

Associated Genetic Biomarkers

CCND1
CCND1 Amplification
CCND2
CCND2 Amplification
CCND3
CCND3 Amplification
CDK4
CDK4 Amplification
CDK6
CDK6 Amplification
CDKN2A
CDKN2A Loss
EWSR1
EWSR1 Fusion
IDH1
IDH1 Codon 132 Missense
IDH1 Mutation
IDH1 R132C
IDH1 R132G
IDH1 R132H

IDH1 R132L
IDH1 R132S
RB1 Expression
UGT1A1 *1/*28
UGT1A1 *1/*6
UGT1A1 *1/*60
UGT1A1 *28/*28
UGT1A1 *6/*6
UGT1A1 *60/*60

Overview

NCI Definition: A malignant cartilaginous matrix-producing mesenchymal neoplasm arising from the bone and soft tissue. It usually affects middle-aged to elderly adults. The pelvic bones, ribs, shoulder girdle, and long bones are the most common sites of involvement. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion. [1]

Biomarker-Directed Therapies

View Therapies for Chondrosarcoma

Of the biomarker-directed therapies for chondrosarcoma, 0 are FDA-approved in at least one setting and 1 has NCCN guidelines in at least one setting [3].

Ivosidenib +

Disease is predicted to be sensitive: -

Biomarker Criteria:

Sample must match one or more of the following:

IDH1 R132C, IDH1 R132G, IDH1 R132H, IDH1 R132L, IDH1 R132S

Clinical Setting(s): Metastatic (NCCN)

Note: Recommended by NCCN for conventional (grades 1-3) or dedifferentiated chondrosarcoma with susceptible IDH1 mutations.

Biomarker Criteria: Sample must match one or more of the following: IDH1 R132C, IDH1 R132G, IDH1 R132H, IDH1 R132L, IDH1 R132S	Clinical Setting(s): Metastatic (NCCN)
	Note: Recommended by NCCN for conventional (grades 1-3) or dedifferentiated chondrosarcoma with susceptible IDH1 mutations.

Clinical Trials

View Clinical Trials for Chondrosarcoma

There are 12 clinical trials for chondrosarcoma, of which 12 are open and 0 are completed or closed. Of the trials that contain chondrosarcoma as an inclusion criterion, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), and 7 are phase 2 (7 open).

IDH1, CCND1, and CCND2 are the most frequent gene inclusion criteria for chondrosarcoma clinical trials [3].

Trials Investigating Chondrosarcoma by Gene and Recruiting Status

Nivolumab, abemaciclib, and atezolizumab are the most common interventions in chondrosarcoma clinical trials.

Drugs Being Investigated in Chondrosarcoma Trials by Recruiting Status

Significant Genes in Chondrosarcoma

AKT1 +

AKT1 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT2 +

AKT2 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT3 +

AKT3 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CCND1 +

CCND1 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCND2 +

CCND2 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND2 status and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCND3 +

CCND3 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND3 status and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK4 +

CDK4 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK6 +

CDK6 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDKN2A +

CDKN2A is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CRKL +

CRKL is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

EWSR1 +

EWSR1 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains EWSR1 status and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

IDH1 +

IDH1 is an inclusion eligibility criterion in 3 clinical trials for chondrosarcoma, of which 3 are open and 0 are closed. Of the trials that contain IDH1 status and chondrosarcoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

Ivosidenib has evidence of efficacy in patients with IDH1 mutation in chondrosarcoma [3].

MTOR +

MTOR is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PDGFRA +

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3CA +

PIK3CA is an inclusion eligibility criterion in 2 clinical trials for chondrosarcoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CA status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PIK3CG +

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R1 +

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R2 +

PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PTEN +

PTEN is an inclusion eligibility criterion in 2 clinical trials for chondrosarcoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RICTOR +

RICTOR is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RPTOR +

RPTOR is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TSC1 +

TSC1 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TSC2 +

TSC2 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

Disease Details

Synonyms

CHONDROSARCOMA, MALIGNANT, Soft tissue chondrosarcoma

Parent(s)

Malignant Connective and Soft Tissue Neoplasm

Children

Dedifferentiated Chondrosarcoma, Localized Chondrosarcoma, Periosteal Chondrosarcoma, Clear Cell Chondrosarcoma, Myxoid Chondrosarcoma, and Mesenchymal Chondrosarcoma

OncoTree Name

Chondrosarcoma

OncoTree Code

CHS

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Chondrosarcoma

Back to Diseases List

Associated Genetic Biomarkers

Overview

Biomarker-Directed Therapies

Clinical Trials

Significant Genes in Chondrosarcoma

Disease Details

References

About

Molecular Medicine

Content Types